LIVIVO - Search results -

Search results

Result 1 - 10 of total 11

Search options

Article ; Online: Identifying variables predictive of success: The next step in alternatives to psychiatric hospitalization research.

Sheridan, Edward P / Zuskar, Deborah M / Walsh, Susan F / O'Brien, Steve

2022 Volume 17, Issue 4, Page(s) 356–368

Abstract: This investigation addresses two issues central to psychiatric hospitalization: (1) Can alternative treatments be effective? and (2) How can patients appropriate for the alternatives be identified? This random design study found that a majority of ... ...

Abstract	This investigation addresses two issues central to psychiatric hospitalization: (1) Can alternative treatments be effective? and (2) How can patients appropriate for the alternatives be identified? This random design study found that a majority of patients assessed as requiring immediate psychiatric hospitalization could utilize a combination of emergency housing and outpatient treatment to avoid hospitalization. Five key variables examined at intake proved useful in predicting ability to succeed in the alternative treatment setting. Patients who failed in the alternative setting had trouble utilizing leisure time, were grandiose, exhibited eating problems, had difficulty with family, and showed an absence of paranoia.
Language	English
Publishing date	2022-01-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	1491194-2
ISSN	1520-6629 ; 0090-4392
ISSN (online)	1520-6629
ISSN	0090-4392
DOI	10.1002/1520-6629(198910)17:4<356::AID-JCOP2290170408>3.0.CO;2-M
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.

Sessa, Ben / Sakal, Chloe / O'Brien, Steve / Nutt, David

BMJ case reports

2019 Volume 12, Issue 7

Abstract: We present the preliminary data in an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder. At ... ...

Abstract	We present the preliminary data in an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder. At this stage, seven participants have completed the full 8-week MDMA-assisted psychotherapy course, including two therapy sessions each with MDMA. This paper focuses on the safety and tolerability of the therapeutic course for the first four participants to complete treatment. Longer-term outcomes of drinking behaviour will be presented later when the full project data are published. Results show all four participants have successfully tolerated the treatment. There have been no serious adverse events related to MDMA, no unexpected physiological responses to the MDMA sessions or changes to blood results or electrocardiograms, measured before and after the 8-week course. We conclude that the treatment is well- tolerated and are making plans to expand the project into a randomised placebo-controlled study.
MeSH term(s)	Adult ; Alcohol Deterrents/administration & dosage ; Alcohol Deterrents/adverse effects ; Alcoholism/rehabilitation ; Combined Modality Therapy ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage ; N-Methyl-3,4-methylenedioxyamphetamine/adverse effects ; Psychotherapy/methods ; Treatment Outcome
Chemical Substances	Alcohol Deterrents ; N-Methyl-3,4-methylenedioxyamphetamine (KE1SEN21RM)
Language	English
Publishing date	2019-07-15
Publishing country	England
Document type	Case Reports ; Journal Article
ISSN	1757-790X
ISSN (online)	1757-790X
DOI	10.1136/bcr-2019-230109
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: An mHealth Design to Promote Medication Safety in Children with Medical Complexity.

Jolliff, Anna / Coller, Ryan J / Kearney, Hannah / Warner, Gemma / Feinstein, James A / Chui, Michelle A / O'Brien, Steve / Willey, Misty / Katz, Barbara / Bach, Theodore D / Werner, Nicole E

Applied clinical informatics

2023 Volume 15, Issue 1, Page(s) 45–54

Abstract: Background: Children with medical complexity (CMC) are uniquely vulnerable to medication errors and preventable adverse drug events because of their extreme polypharmacy, medical fragility, and reliance on complicated medication schedules and routes ... ...

Abstract	Background: Children with medical complexity (CMC) are uniquely vulnerable to medication errors and preventable adverse drug events because of their extreme polypharmacy, medical fragility, and reliance on complicated medication schedules and routes managed by undersupported family caregivers. There is an opportunity to improve CMC outcomes by designing health information technologies that support medication administration accuracy, timeliness, and communication within CMC caregiving networks. Objectives: The present study engaged family caregivers, secondary caregivers, and clinicians who work with CMC in a codesign process to identify: (1) medication safety challenges experienced by CMC caregivers and (2) design requirements for a mobile health application to improve medication safety for CMC in the home. Methods: Study staff recruited family caregivers, secondary caregivers, and clinicians from a children's hospital-based pediatric complex care program to participate in virtual codesign sessions. During sessions, the facilitator-guided codesigners in generating and converging upon medication safety challenges and design requirements. Between sessions, the research team reviewed notes from the session to identify design specifications and modify the prototype. After design sessions concluded, each session recording was reviewed to confirm that all designer comments had been captured. Results: A total of Conclusion: This study generated design requirements for a tool that may improve medication safety by creating distributed situation awareness within the caregiving network. The next steps are to pilot test tools that integrate these design requirements for usability and feasibility, and to conduct a randomized control trial to determine if use of these tools reduces medication errors.
MeSH term(s)	Child ; Humans ; Caregivers ; Communication ; Telemedicine
Language	English
Publishing date	2023-11-21
Publishing country	Germany
Document type	Journal Article ; Research Support, N.I.H., Extramural
ISSN	1869-0327
ISSN (online)	1869-0327
DOI	10.1055/a-2214-8000
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.

Sessa, Ben / Aday, Jacob S / O'Brien, Steve / Curran, H Valerie / Measham, Fiona / Higbed, Laurie / Nutt, David J

Journal of psychopharmacology (Oxford, England)

2021 Volume 36, Issue 3, Page(s) 360–367

Abstract: Background: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in ... ...

Abstract	Background: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in mood and cognition during the days following dosing, also known as 'Blue Mondays', have been raised as limitations to its clinical use. Although these changes have been well-documented among recreational users, there are critical confounds to these reports that limit generalizability to clinically administered MDMA. Aims: Here, we aimed to evaluate the evidence basis for the negative side effects associated with MDMA as well as inform our understanding of the drug's post-acute effects in a clinical context with an open-label study. Methods: The current open-label study examined MDMA therapy for alcohol use disorder (AUD; Results: Participants maintained a positive mood during the week following drug administration in a clinical context. Relative to baseline, self-reported sleep quality improved at the 3- and 6-month follow-ups. Finally, no participants reported using or desiring to use illicit MDMA, and the anecdotal reports indicated that they perceived the treatment favourably. Conclusion: The results support the overall safety and tolerability of clinically administered MDMA and, importantly, suggest that the 'come downs' previously associated with the substance may be explained by confounds in research relating to the illicit sourcing of the drug and specific environmental setting for recreational consumption.
MeSH term(s)	Affect ; Alcohol Drinking/psychology ; Alcoholism/drug therapy ; Cognition ; Hallucinogens/adverse effects ; Humans ; N-Methyl-3,4-methylenedioxyamphetamine/adverse effects
Chemical Substances	Hallucinogens ; N-Methyl-3,4-methylenedioxyamphetamine (KE1SEN21RM)
Language	English
Publishing date	2021-12-13
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	639313-5
ISSN	1461-7285 ; 0269-8811
ISSN (online)	1461-7285
ISSN	0269-8811
DOI	10.1177/02698811211055809
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2311: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: An mHealth Design to Promote Medication Safety in Children with Medical Complexity

Jolliff, Anna / Coller, Ryan J. / Kearney, Hannah / Warner, Gemma / Feinstein, James A. / Chui, Michelle A. / O'Brien, Steve / Willey, Misty / Katz, Barbara / Bach, Theodore D. / Werner, Nicole E.

Applied Clinical Informatics

2023 Volume 15, Issue 01, Page(s) 45–54

Abstract	Background: Children with medical complexity (CMC) are uniquely vulnerable to medication errors and preventable adverse drug events because of their extreme polypharmacy, medical fragility, and reliance on complicated medication schedules and routes managed by undersupported family caregivers. There is an opportunity to improve CMC outcomes by designing health information technologies that support medication administration accuracy, timeliness, and communication within CMC caregiving networks. Objectives: The present study engaged family caregivers, secondary caregivers, and clinicians who work with CMC in a codesign process to identify: (1) medication safety challenges experienced by CMC caregivers and (2) design requirements for a mobile health application to improve medication safety for CMC in the home. Methods: Study staff recruited family caregivers, secondary caregivers, and clinicians from a children's hospital-based pediatric complex care program to participate in virtual codesign sessions. During sessions, the facilitator-guided codesigners in generating and converging upon medication safety challenges and design requirements. Between sessions, the research team reviewed notes from the session to identify design specifications and modify the prototype. After design sessions concluded, each session recording was reviewed to confirm that all designer comments had been captured. Results: A total of N = 16 codesigners participated. Analyses yielded 11 challenges to medication safety and 11 corresponding design requirements that fit into three broader challenges: giving the right medication at the right time; communicating with others about medications; and accommodating complex medical routines. Supporting quotations from codesigners and prototype features associated with each design requirement are presented. Conclusion: This study generated design requirements for a tool that may improve medication safety by creating distributed situation awareness within the caregiving network. The next steps are to pilot test tools that integrate these design requirements for usability and feasibility, and to conduct a randomized control trial to determine if use of these tools reduces medication errors.
Keywords	medication management ; polypharmacy ; pediatrics ; user-centered design ; social networks
Language	English
Publishing date	2023-11-21
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ISSN	1869-0327
ISSN (online)	1869-0327
DOI	10.1055/a-2214-8000
Database	Thieme publisher's database

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder.

Sessa, Ben / Higbed, Laurie / O'Brien, Steve / Durant, Claire / Sakal, Chloe / Titheradge, Daniel / Williams, Tim M / Rose-Morris, Anna / Brew-Girard, Elsa / Burrows, Sam / Wiseman, Chantelle / Wilson, Sue / Rickard, James / Nutt, David J

Journal of psychopharmacology (Oxford, England)

2021 Volume 35, Issue 4, Page(s) 375–383

Abstract: Background: 3,4-methylenedioxymethamphetamine (MDMA) therapy has qualities that make it potentially well suited for patients with addictions, but this has never been explored in a research study. We present data from the Bristol Imperial MDMA in ... ...

Abstract	Background: 3,4-methylenedioxymethamphetamine (MDMA) therapy has qualities that make it potentially well suited for patients with addictions, but this has never been explored in a research study. We present data from the Bristol Imperial MDMA in Alcoholism (BIMA) study. This is the first MDMA addiction study, an open-label safety and tolerability proof-of-concept study investigating the potential role for MDMA therapy in treating patients with alcohol use disorder (AUD). Aims: This study aimed to assess if MDMA-assisted psychotherapy can be delivered safely and can be tolerated by patients with AUD post detoxification. Outcomes regarding drinking behaviour, quality of life and psychosocial functioning were evaluated. Methods: Fourteen patients with AUD completed a community alcohol detoxification and received an eight-week course of recovery-based therapy. Participants received two sessions with MDMA (187.5 mg each session). Psychological support was provided before, during and after each session. Safety and tolerability were assessed alongside psychological and physiological outcome measures. Alcohol use behaviour, mental well-being and functioning data were collected for nine months after alcohol detoxification. Results: MDMA treatment was well tolerated by all participants. No unexpected adverse events were observed. Psychosocial functioning improved across the cohort. Regarding alcohol use, at nine months post detox, the average units of alcohol consumption by participants was 18.7 units per week compared to 130.6 units per week before the detox. This compares favourably to a previous observational study (the 'Outcomes' study) by the same team with a similar population of people with AUD. Conclusions: This study provides preliminary support for the safety and tolerability of a novel intervention for AUD post detox. Further trials to examine better the therapeutic potential of this approach are now indicated.
MeSH term(s)	Alcohol Drinking/psychology ; Alcohol Drinking/therapy ; Alcoholism/diagnosis ; Alcoholism/physiopathology ; Alcoholism/psychology ; Alcoholism/therapy ; Combined Modality Therapy ; Drug Monitoring/methods ; Female ; Hallucinogens/administration & dosage ; Hallucinogens/adverse effects ; Humans ; Male ; Middle Aged ; N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage ; N-Methyl-3,4-methylenedioxyamphetamine/adverse effects ; Outcome Assessment, Health Care ; Proof of Concept Study ; Psychiatric Status Rating Scales ; Psychosocial Functioning ; Psychotherapy/methods ; Quality of Life ; Recovery of Function ; Treatment Outcome ; United Kingdom
Chemical Substances	Hallucinogens ; N-Methyl-3,4-methylenedioxyamphetamine (KE1SEN21RM)
Language	English
Publishing date	2021-02-18
Publishing country	United States
Document type	Journal Article
ZDB-ID	639313-5
ISSN	1461-7285 ; 0269-8811
ISSN (online)	1461-7285
ISSN	0269-8811
DOI	10.1177/0269881121991792
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2311: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Tax and accounting for treasurers

Rayner, Jeremy / O'Brien, Steve

Journal of corporate treasury management : the official publication of the Finance and Treasury Association Vol. 2, No. 1 (2008/09), p. 82-89

why hedging is getting more complex

2008 Volume 2, Issue 1, Page(s) 82–89

Author's details	Jeremy Rayner; Steve O'Brien
Keywords	Hedging ; Betriebliche Finanzwirtschaft ; Bilanzierungsgrundsätze ; Großbritannien
Language	English
Size	graph. Darst.
Publisher	Henry Stewart Publ.
Publishing place	London
Document type	Article
ZDB-ID	2408935-7
Database	ECONomics Information System

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Roy, Lydia / Guilhot, Joëlle / Krahnke, Tillmann / Guerci-Bresler, Agnès / Druker, Brian J / Larson, Richard A / O'Brien, Steve / So, Charlene / Massimini, Giorgio / Guilhot, François

Blood

2006 Volume 108, Issue 5, Page(s) 1478–1484

Abstract: In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic ... ...

Abstract	In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation, and overall survival were significantly higher with imatinib compared with IFN/Ara-C (P < .001, P = .004, and P < .001, respectively). Improved overall survival was also confirmed within different Sokal prognostic risk groups. Of interest, among all patients who achieved major cytogenetic response or CCyR at 12 months, the survival rate was similar irrespective of their treatment. In conclusion, within the limitation of this historical comparison, there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C.
MeSH term(s)	Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Benzamides ; Bone Marrow Transplantation ; Clinical Trials, Phase III as Topic ; Cytarabine/therapeutic use ; Disease Progression ; Female ; Humans ; Imatinib Mesylate ; Interferon-alpha/therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality ; Male ; Middle Aged ; Piperazines/therapeutic use ; Pyrimidines/therapeutic use ; Retrospective Studies ; Splenomegaly/epidemiology ; Survival Analysis ; Treatment Failure ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Benzamides ; Interferon-alpha ; Piperazines ; Pyrimidines ; Cytarabine (04079A1RDZ) ; Imatinib Mesylate (8A1O1M485B)
Language	English
Publishing date	2006-04-20
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2006-02-001495
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunologic profile of highly exposed yet HIV type 1-seronegative men.

Yang, Otto O / Boscardin, W John / Matud, Jose / Hausner, Mary Ann / Hultin, Lance E / Hultin, Patricia M / Shih, Roger / Ferbas, John / Siegal, Frederick P / Shodell, Michael / Shearer, Gene M / Grene, Edith / Carrington, Mary / O'Brien, Steve / Price, Charles B / Detels, Roger / Jamieson, Beth D / Giorgi, Janis V

AIDS research and human retroviruses

2002 Volume 18, Issue 14, Page(s) 1051–1065

Abstract: The host immune factors that determine susceptibility to HIV-1 infection are poorly understood. We compared multiple immunologic parameters in three groups of HIV-1-seronegative men: 14 highly exposed (HR10), 7 previously reported possibly to have ... ...

Abstract	The host immune factors that determine susceptibility to HIV-1 infection are poorly understood. We compared multiple immunologic parameters in three groups of HIV-1-seronegative men: 14 highly exposed (HR10), 7 previously reported possibly to have sustained transient infection (PTI), and a control group of 14 low risk blood bank donors (BB). Virus-specific cellular immune assays were performed for CD4(+) T helper cell responses, CD8(+) cytotoxic T lymphocyte activity, CD8(+) cell chemokine release, and CD8(+) cell-derived antiviral soluble factor activity. General immune parameters evaluated included CCR5 genotype and phenotype, interferon alpha production by PBMCs, leukocyte subset analysis, and detailed T lymphocyte phenotyping. Comparisons revealed no detectable group-specific differences in measures of virus-specific immunity. However, the HR10 group differed from the BB group in several general immune parameters, having higher absolute monocyte counts, higher absolute CD8(+) T cell counts and percentages, lower naive and higher terminal effector CD8(+) cells, and lower levels of CD28(+)CD8(+) cells. These changes were not associated with seropositivity for other chronic viral infections. The PTI men appeared to have normal levels of monocytes and slightly elevated levels of CD8(+) T cells (also with increased effector and decreased naive cells). Although we cannot entirely exclude the contribution of other chronic viral infections, these findings suggest that long-lived systemic cellular antiviral immunity as detected by our assays is not a common mechanism for resistance to infection, and that resistance may be multifactorial. General immune parameters reflected by CD8(+) T cell levels and activation, and monocyte concentrations may affect the risk of infection with HIV-1, and/or serve as markers of exposure.
MeSH term(s)	Adult ; Amino Acid Sequence ; Chronic Disease ; Cytokines/biosynthesis ; HIV Seronegativity/immunology ; HIV-1/immunology ; Humans ; Immunity, Cellular ; Immunophenotyping ; Interferon-gamma/biosynthesis ; Male ; Peptides/chemical synthesis ; Peptides/chemistry ; Peptides/immunology ; Receptors, CCR5/metabolism ; Retroviridae Proteins/chemistry ; T-Lymphocytes, Cytotoxic/immunology ; T-Lymphocytes, Helper-Inducer/immunology ; Virus Diseases/immunology
Chemical Substances	Cytokines ; Peptides ; Receptors, CCR5 ; Retroviridae Proteins ; Interferon-gamma (82115-62-6)
Language	English
Publishing date	2002-09-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	639130-8
ISSN	1931-8405 ; 0889-2229
ISSN (online)	1931-8405
ISSN	0889-2229
DOI	10.1089/08892220260235416
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1928: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Sawyers, Charles L / Hochhaus, Andreas / Feldman, Eric / Goldman, John M / Miller, Carole B / Ottmann, Oliver G / Schiffer, Charles A / Talpaz, Moshe / Guilhot, Francois / Deininger, Michael W N / Fischer, Thomas / O'Brien, Steve G / Stone, Richard M / Gambacorti-Passerini, Carlo B / Russell, Nigel H / Reiffers, Jose J / Shea, Thomas C / Chapuis, Bernard / Coutre, Steven /

Tura, Sante / Morra, Enrica / Larson, Richard A / Saven, Alan / Peschel, Christian / Gratwohl, Alois / Mandelli, Franco / Ben-Am, Monique / Gathmann, Insa / Capdeville, Renaud / Paquette, Ronald L / Druker, Brian J

Blood

2002 Volume 99, Issue 10, Page(s) 3530–3539

Abstract: Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. ... ...

Abstract	Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Imatinib (Glivec, formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl tyrosine kinase. A total of 260 patients with CML were enrolled in a phase II trial, of whom 229 had a confirmed diagnosis of CML in blast crisis. Patients were treated with imatinib in daily oral doses of 400 mg or 600 mg. Imatinib induced hematologic responses in 52% of patients and sustained hematologic responses lasting at least 4 weeks in 31% of patients, including complete hematologic responses in 8%. For patients with a sustained response, the estimated median response duration was 10 months. Imatinib induced major cytogenetic responses in 16% of patients, with 7% of the responses being complete. Median survival time was 6.9 months. Nonhematologic adverse reactions were frequent but generally mild or moderate. Episodes of severe cytopenia were also frequent and were attributable to the underlying condition and treatment with imatinib. Drug-related adverse events led to discontinuation of therapy in 5% of patients, most often because of cytopenia, skin disorders, or gastrointestinal reactions. These results demonstrate that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis. Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs.
MeSH term(s)	Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Benzamides ; Blast Crisis/diagnosis ; Blast Crisis/drug therapy ; Blast Crisis/mortality ; Blood Cell Count ; Cytogenetic Analysis ; Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/therapeutic use ; Female ; Fusion Proteins, bcr-abl/antagonists & inhibitors ; Humans ; Imatinib Mesylate ; Kinetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality ; Male ; Middle Aged ; Piperazines/adverse effects ; Piperazines/therapeutic use ; Prognosis ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use ; Survival Rate ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Benzamides ; Enzyme Inhibitors ; Piperazines ; Pyrimidines ; Imatinib Mesylate (8A1O1M485B) ; Fusion Proteins, bcr-abl (EC 2.7.10.2)
Language	English
Publishing date	2002-05-15
Publishing country	United States
Document type	Clinical Trial ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.v99.10.3530
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito